Where to buy retatrutide.

A 2026 sourcing guide for retatrutide as a research reference compound — the triple GIP/GLP-1/glucagon agonist studied in Eli Lilly’s Phase II and ongoing Phase III TRIUMPH program. Pre-approval status and synthesis complexity make identity verification especially important for this compound.

Buying guide8 min read

Key takeaway

Retatrutide (development code LY3437943) is Eli Lilly’s triple GIP/GLP-1/glucagon agonist under clinical investigation. Currently in Phase III (the TRIUMPH program). Not FDA-approved. Available as a research reference compound for laboratory use. On November 17, 2026, US research suppliers listed 10 mg vials at $80.00–$105.00 ($8.00–$10.50 per mg). Synthesis is complex (39 residues plus a fatty-acid modification). The single biggest red flag: vendors selling under codenames like FG-1, FG-2, FG-blend without disclosing the chemical identity. Identity transparency is non-negotiable for a peptide this complex.

At a glance

Article typeBuying guide
Main guideRetatrutide: complete guide
Regulatory statusIn clinical trials“It's in Phase III development under Lilly's TRIUMPH program” (Retatrutide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited2 in this article · 13 across 11 articles on Retatrutide
ProductRetatrutide product page

Retatrutide is the triple GIP/GLP-1/glucagon agonist that produced 24.2% mean weight reduction at the highest dose in the 2023 NEJM Phase II trial — the largest pharmacological weight-reduction magnitude reported in that trial cohort (Jastreboff et al., 2023). It’s also not FDA-approved. Where to buy retatrutide in 2026 means one channel only: a research-supply vendor. This guide covers current research-grade prices, the FG-series codename problem plaguing the market, and the mass-spec verification that confirms what’s actually in the vial.

Get new research first

Research updates
Citation-anchored summaries New-batch COA alerts Unsubscribe anytime

One short email when new peptide research drops or a new lab-verified batch lands — written from primary sources, no filler.

The sourcing summary: A credible vendor sells it as “retatrutide,” not under a codename. A batch-matched CoA from an ISO 17025-accredited lab should show HPLC purity ≥98% and mass-spec confirming the lipid-modified peptide. On November 17, 2026, US research suppliers listed 10 mg vials at $80.00–$105.00. Our retatrutide price page has the full table.

Research sourcing channels in 2026

Retatrutide is still in clinical trials. That dramatically narrows the available channels. Three channels exist, but only one is accessible for research procurement:

  • Doctor’s prescription: Not available. Retatrutide isn’t FDA-approved yet. No pharmacy can fill a prescription for it.
  • Compounding pharmacy: Not available. The 503A compounding channel requires either FDA approval or a Drug Shortage listing for the active ingredient. Retatrutide has neither.
  • Research-supply vendor: The only channel. Lyophilized powder under Research Use Only labeling. No prescription needed. Buyer must use it for research, not human consumption.

Research-supply channel limitations: No physician oversight. No prescribed dose. No insurance. No FDA-regulated batch testing — quality assurance relies entirely on the vendor’s third-party CoA. The molecule is patented. Lilly holds active IP. The grey-market synthesis landscape is unsettled and could shift as Phase III completes.

Compound identity and structure

Retatrutide is a 39-amino-acid peptide engineered to engage three receptors at once: GIP, GLP-1, and glucagon. These are the gut and pancreatic hormones that control insulin release, appetite, and energy expenditure. The triple-agonist design adds glucagon receptor activation to the GIP/GLP-1 platform that tirzepatide pioneered (Jastreboff et al., 2023).

The molecule also carries a fatty-acid side chain. That side chain helps it bind to albumin (a blood protein) and extends its half-life.

The backbone weighs about 4,731 Da unmodified. With the lipid modification, the observed mass on a CoA lands in the high-4,900s. Long sequence, lipid modification, multiple basic residues that need careful counterion management. Retatrutide is at the high end of synthesis complexity for any peptide. Cost reflects the chemistry, not vendor markup.

“

Retatrutide led to substantial weight reduction in adults with obesity. At 48 weeks, the highest-dose group lost a mean of 24.2% of body weight.

— Jastreboff et al., NEJM, 2023 (Phase II, n=338)

Figure 1

Retatrutide Phase II dose response — 48-week body-weight reduction by arm.

Mean percent weight change from baseline at 48 weeks, by treatment arm, in the Phase II Jastreboff et al. trial (n=338). The 12 mg arm produced the largest pharmacological body-weight-reduction magnitude documented at the time of publication.

0% -5% -15% -25% -30% Placebo -2.1% 1 mg -7.2% 4 mg -12.9% 8 mg -17.5% 12 mg -24.2% Tirzepatide 15 mg (ref.) -22.5% (SURMOUNT-1)

Source: Jastreboff et al., 2023, NEJM (retatrutide Phase II); tirzepatide reference: SURMOUNT-1 trial.

The four checks that matter for retatrutide

The standard eight vendor criteria apply. Four are sharper here, and the first one is unique to this peptide.

1. Identity transparency: no codenames, ever

Credible suppliers sell retatrutide under its actual name. Some grey-market vendors sell what appear to be retatrutide-class compounds under codes like FG-1, FG-2, FG-3, FG-blend. They refuse to confirm the chemical identity on the product page or CoA.

Based on pricing and catalog placement, these codenamed compounds are widely believed to be GLP-1-class molecules sold under codes to dodge trademark, intellectual-property, and regulatory scrutiny. When purchased, an FG-series compound offers no way to verify chemical identity without independent mass-spec testing.

The rule: if it’s not labeled retatrutide on both the product page and the CoA, it isn’t retatrutide.

2. Mass-spec must match the lipid-modified peptide

The observed mass on the CoA should reflect the 39-residue backbone plus the fatty-acid modification. A CoA reporting just the unmodified backbone mass indicates incomplete synthesis or substitution. For a peptide this complex, the mass-spec identity line is the single most reliable check for compound authenticity.

3. Storage stability documentation

The lipid modification and basic residue content make retatrutide more sensitive to freeze-thaw cycles than simpler peptides. A research-grade vendor should document how long the lyophilized vial keeps potency at −20°C versus refrigerated reconstituted solution. Vendors that supply no stability data on a peptide this complex are skipping work that matters.

4. Synthesis source disclosure

Reputable suppliers will disclose, on request, where the peptide was synthesized: in-house, a contract lab, or a named overseas manufacturer. For retatrutide specifically, this matters because Lilly holds active patents. Sources that decline to name their facility may be using channels that create downstream legal exposure or quality uncertainty.

Retatrutide

39 aa GIP/GLP-1/Glucagon Lipid-modified

The triple-agonist molecule from the 2023 NEJM Phase II trial. Sold under the actual peptide name, with a batch-matched third-party CoA. Mass-spec identity confirmed for the lipid-modified 39-residue peptide.

View retatrutide

2026 pricing benchmarks

We checked US research supplier product pages on November 17, 2026. Listed single-vial prices, before shipping and codes:

  • 5 mg vial: $39.99 at the one supplier that showed a 5 mg price.
  • 10 mg vial: $80.00–$105.00 ($8.00–$10.50 per mg).
  • 15 mg to 40 mg vials: $99.99–$169.99. Larger vials cost less per mg, as low as $4.00 per mg.
  • Promotions: Buy-one-get-one offers and pack discounts change the effective price from week to week.

The full table, with each supplier and source, is on our retatrutide price page.

A low price is not proof of a problem. It does leave less room for purification and third-party testing. A listing far below the rest of the market deserves a closer look. On November 17, 2026, one US listing offered a 10-vial pack for $189.00, or $18.90 a vial. At that level, ask for the specific lot’s test report before ordering. Mass-spec CoA testing shows whether the vial holds retatrutide.

As of May 2026, retatrutide is in Phase III. The TRIUMPH program is enrolling. No FDA approval. No EMA approval. Three things follow:

  • Research-compound sales are legal. Retatrutide can ship in the U.S. as a Research Use Only reference compound. Use must stay consistent with research intent.
  • Therapeutic sales are illegal. Marketing retatrutide for obesity, with dosing instructions or clinical claims, crosses into FDA jurisdiction. Credible suppliers avoid this.
  • Patents are active. Eli Lilly holds the IP on LY3437943. The grey-market synthesis landscape is unsettled. The picture could shift as Phase III completes.

Red flags specific to retatrutide

  • Sold under codenames (FG-series or similar) without chemical identity disclosure. The biggest retatrutide-specific red flag.
  • Pricing far below other listings. 10 mg vials listed at $80.00–$105.00 on November 17, 2026. A price far under that range is a reason to ask for the lot’s test report.
  • Mass-spec CoA missing or showing only the unmodified backbone. The lipid modification is essential. Confirmation has to cover the modified molecule.
  • Therapeutic dosing instructions on the product page. Dosing directions are selling-for-human-use language. The FDA notices.
  • No third-party ISO 17025 lab partner. Internal QC isn’t enough for a peptide this complex.
  • Inconsistent or absent lot numbering. Each batch should have its own lot number, its own CoA, and its own retest date.

Retatrutide

10 mg ≥99% pure Lyophilized

39-residue triple incretin agonist with fatty-acid modification. The same reference compound cited across the Jastreboff et al. Phase II trial. A lot-specific third-party CoA with HPLC and mass-spec identity ships with every order.

Learn more

Frequently asked questions

Is retatrutide legal to buy in the USA?

Yes, as a research reference compound. The Phase III TRIUMPH program is still ongoing. Not FDA-approved yet. Selling for human consumption is illegal. Buying from a vendor that ships it under Research Use Only labeling isn’t.

How much should research-grade retatrutide cost?

On November 17, 2026, US research suppliers listed 10 mg vials at $80.00–$105.00 ($8.00–$10.50 per mg). A price far below that range is a reason to verify the identity. See retatrutide price for the full table.

What is the FG-series and why does it matter?

Some grey-market vendors sell compounds under codes like “FG-1,” “FG-2,” or “FG-blend” with no chemical identity disclosure. Based on pricing and catalog placement, these are widely believed to be retatrutide-class molecules sold under codes to dodge trademark and regulatory scrutiny. Without third-party mass-spec testing, identity cannot be verified. A credible retatrutide vendor lists it under the actual compound name with a clear CoA.

What should a retatrutide Certificate of Analysis show?

HPLC purity ≥98% with chromatogram. Mass-spec identity matching the lipid-modified peptide (unmodified backbone ~4,731 Da; observed mass is higher with the lipid). Water content via Karl Fischer titration. Counterion content. An ISO 17025-accredited lab on the report.

Why is retatrutide so much more expensive than BPC-157 or GHK-Cu?

Retatrutide is 39 residues with a fatty-acid modification. BPC-157 is 15 residues, unmodified. GHK-Cu is 3 residues. Each extra amino acid in solid-phase synthesis adds a coupling step plus more purification. Modifications add specialized chemistry. That synthesis work is what raises the cost per mg.

How does retatrutide compare to tirzepatide for research?

Both are research-relevant incretin agonists. Tirzepatide is FDA-approved as Mounjaro and Zepbound. As a dual GIP/GLP-1 agonist, the SURMOUNT-1 trial reported 22.5% mean weight reduction at the highest dose (Jastreboff et al., 2022). Retatrutide adds glucagon receptor agonism and the Phase II trial reported 24.2% at its highest dose (Jastreboff et al., 2023). See retatrutide vs tirzepatide for the head-to-head.

What to know now

  • Identity transparency is the #1 red flag. Codenames like FG-1, FG-2, FG-blend without chemical disclosure mean grey-market sourcing.
  • 10 mg vials listed at $80.00–$105.00 at US research suppliers on November 17, 2026. Far below that, verify the identity.
  • Mass-spec CoA must confirm the lipid-modified molecule, not just the unmodified backbone.
  • Phase III is ongoing. Research-compound sales are legal. Therapeutic sales aren’t.
  • Lilly holds active patents. Synthesis source disclosure matters.

What we’re watching

The Phase III TRIUMPH readouts start publishing late 2026 through 2027. That’ll set the next pricing and regulatory benchmark for retatrutide. FDA approval (likely 2027–2028 if Phase III replicates Phase II) would reshape the market overnight. Post-approval, retatrutide becomes available as a compounded therapeutic through 503A pharmacies, which would change both pricing and the regulatory framing for non-clinical use. The FG-series codename trend is also worth tracking. If FDA enforcement targets the codename obfuscation, the sourcing landscape changes immediately.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Jastreboff 2023, New England Journal of Medicine; Jastreboff 2022, New England Journal of Medicine; International Organization for Standardization 2017; U.S. Food and Drug Administration 2023, Section 503A of the Federal Food, Drug, and Cosmetic Act; ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) . clinicaltrials.gov retatrutide. All 5 citations

Back to the research library

References

  1. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
  2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  3. International Organization for Standardization. (2017). ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. https://www.iso.org/standard/66912.html
  4. U.S. Food and Drug Administration. (2023). Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
  5. ClinicalTrials.gov. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1). clinicaltrials.gov retatrutide